ClinicalTrials.gg
RecruitingNCT06811545CPUpdated Oct 23, 2026

Evaluating the Effects of an Electrical Stimulator on Improving the Walking Ability of Children With Cerebral Palsy

An interventional study of Neuromuscular Electrical Stimulation (NMES) in Cerebral Palsy Children and Healthy Adults, sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to participants aged 7 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University of Nebraska · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 23, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
7 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 372 studies in Cerebral Palsy with a site in United States — 74 open to participants now, 102 under way, none of them phase 3. Cerebral Palsy · United States.

Planned enrollment
53rd of 296
65 · median 25
Started
2026
with 23 others
No phase
218 of 372
49 open now
Primary completion
2029-06
later than 85 of 101 live
Registered
335th of 372
by date

Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 53rd largest by planned enrollment of the 296 interventional ones that give a count, is one of 24 that started in 2026, is one of 218 with no phase, reaches primary completion later than 85 of the 101 other live ones, and was the 335th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

74 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 7 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 372 studies in Cerebral Palsy with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to see if gentle electrical stimulation can help children with cerebral palsy (CP) walk more easily. This stimulation, called neuromuscular electrical stimulation (NMES), sends small pulses to muscles to help them activate. Researchers will test different ways of using NMES to find out which method works best.

Participants will walk on a treadmill at a comfortable speed while NMES is applied to leg muscles. The study will compare different stimulation settings to see which one helps the most.

Read the detailed description

Children with cerebral palsy (CP) can have trouble with daily tasks such as walking. This raises their risk of disability as they age into their teens. Current treatments are not very effective. In this study, children with CP will walk on a treadmill while receiving neuromuscular electrical stimulation (NMES) on their lower limb muscles, using surface electrodes, while their gait dynamics are assessed, using Inertial Measurement Unit (IMU) sensors. Our proposed study aims to gather preliminary evidence to support the potential efficacy of NMES assistance to muscles across all lower limb joints during walking, i.e., multi-joint NMES assistance. Additionally, we aim to investigate the optimal level of intensity. We intend to quantify neuroprosthetic, i.e., immediate effects during NMES assistance on gait kinematics. 40 children between the ages of 7 to 18 who are diagnosed with spastic diplegic cerebral palsy and GMFCS level I-III, and 25 healthy adults will be recruited for this study. The study consists of one pilot session and two assessment sessions. During the pilot session, participants will walk on the treadmill at their self-selected speed while two IMU sensors measure their shank velocity and acceleration. No stimulation will be applied to the subjects during the pilot session, as we aim to only validate and improve the software that triggers the stimulation during the gait, i.e., our gait phase detection system. During assessment sessions, subjects will walk on a treadmill with and without NMES assistance at their self-selected walking speed. The assessment sessions consist of multiple NMES conditions. Each condition lasts about 1 minute and will be repeated 3 times, with 30 seconds rest between trials for each condition and 5 minutes between each condition. The total walking time will not exceed 30 minutes. Each visit will last about 3 hours. The first session will also include a consent process, which will add an extra 30 minutes. The assessment sessions will begin with a no-stimulation condition and will be followed by multiple NMES conditions consisting of NMES assistance to various lower limb muscle combinations.

03

Conditions studied

  • Cerebral Palsy Children
  • Healthy Adults

Browse trials for

04

Who can participate

Ages eligible
7 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

*Inclusion Criteria*

CP Group:

  • Age 7-18
  • Diagnosis of spastic diplegic cerebral palsy (CP)
  • GMFCS level I-III (be able to walk with or without assistive devices)
  • MIGR \< 40% femoral head covering in acetabulum
  • Crouch, equinus, or jump gait
  • At least 0° passive dorsiflexion range of motion (ROM)
  • Sufficient visuoperceptual, cognitive, and communication skills
  • Seizure-free or well-controlled seizures
  • No other neurological or musculoskeletal disorders (e.g. dystonia, severe scoliosis, hip instability
  • Ability to travel to the University of Nebraska at Omaha two times
  • Ability to communicate pain or discomfort
  • Ability to obtain child assent and obtain parent/guardian consent

Healthy adults (control) group:

  • Adults aged 20 to 40
  • Adults with good physical health
  • Adults with the ability to follow verbal instructions
  • Adults with the ability to walk on a treadmill for 15 minutes
  • No orthopedic surgery on the lower limb within the past 3 months

*Exclusion Criteria*

CP Group:

  • Diagnosis of athetoid or ataxic cerebral palsy (CP)
  • Scoliosis with primary curve > 49%
  • Spinal fusions extending into the pelvis
  • Lower Extremity (LE) joint instability or dislocation
  • Severe tactile
  • LE botulinum injections in the past 6 mo
  • Implanted medical device contraindicative of functional electrical stimulation (FES)
  • Pregnancy
  • Severe LE spasticity (Modified Ashworth Scale score of 4 or greater)
  • History of pulmonary disease limiting exercise tolerance (Asthma Control Test screen)
  • History of cardiac disease (American Heart Association, AH,) screen)
  • Excessive LE joint pain during walking
  • Severely limited range of joint motion/ irreversible muscle contractures, i.e.> 10° knee flexion, >15° hip flexion contractures, or >5° plantarflexion contractures
  • LE surgery or significant injury within 1 yr.

Healthy adults (control) group:

  • Adults with any chronic illnesses or medical conditions that could impact their health.
  • Adults with significant behavioral or emotional issues that could indicate developmental disorders or psychological conditions.
  • Adults with diagnosed developmental disorders (e.g., autism, ADHD, learning disabilities)
  • Adults with surgery on their lower limb within the past 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Cerebral Palsy Group

    The Cerebral Palsy Group (CP), intervention group, will receive a low power electrical stimulation, Neuromuscular Electrical Stimulation (NMES), on different combination of their lower limb muscles while walking on the treadmill.

    Device: Neuromuscular Electrical Stimulation (NMES)

  • Active comparator
    Healthy Adults Group

    The Healthy Adults Group (HA) will receive a similar low power electrical stimulation, Neuromuscular Electrical Stimulation (NMES), as that received by the Cerebral Palsy Group. However, they will will only receive NMES in specific muscle groups and the only variable across conditions will be the power of stimulation.

    Device: Neuromuscular Electrical Stimulation (NMES)

Interventions

  • DeviceNeuromuscular Electrical Stimulation (NMES)

    Children with CP can have trouble with daily tasks such as walking. This raises their risk of disability as they age into their teens. Current treatments are not very effective. In this study, children with CP will walk on a treadmill while receiving NMES on their lower limb muscles, using surface electrodes, while their gait dynamics are assessed. Our proposed study aims to gather preliminary evidence to support the potential efficacy of NMES assistance to muscles across all lower limb joints during walking, i.e., multi-joint NMES assistance. Additionally, the investigators aim to investigate the optimal level of intensity.

06

What researchers measure

Primary outcomes

  1. Gait Variable Index (GDI)

    Gait Variable Index (GDI) is an index of gait pathology based on 15 different kinematic measures (bilaterally) or nine unilaterally. The GDI score ranges from 0 to 100 where 100 represents atypically developing's (TD) normal GDI score.

    Time frame: Baseline (enrollment) and the end of assessment at 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 36 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jun 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 6, 2025
StartActual
Jun 15, 2026was Sep 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jul 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
University of Nebraska at Omaha, Biomechanics Research Building is now Recruiting
Oct 23, 2026
Start date
Sep 2026→Jun 15, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    University of Nebraska at Omaha, Biomechanics Research Building is now Recruiting
    Start date Sep 2026→Jun 15, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06811545
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Jun 15, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Ahad Behboodi, PhD
Contact
abehboodi@unomaha.edu
402-554-7525
Ahad Behboodi, PhD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion